This trial studies how a drug can help improve quality of life for people with psoriasis.
1 Primary · 7 Secondary · Reporting Duration: Up to week 56
Awards & Highlights
2 Treatment Groups
1 of 2
Placebo then Deucravacitinib
1 of 2
250 Total Participants · 2 Treatment Groups
Primary Treatment: Deucravacitinib · Has Placebo Group · Phase 4
Who is running the clinical trial?
Age 18+ · All Participants · 3 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How many sites are currently executing this research trial?
"Arkansas Research Trials, Inc. in North Little Rock and Bakersfield Dermatology Skin Cancer Med.Group in Bakersfield are two of the 28 locations currently recruiting patients for this medical trial; Integrative Skin Science and Research in Sacramento is yet another participating site." - Anonymous Online Contributor
Are there any unoccupied slots in this investigation for participants?
"This particular trial is not accepting any new patients, as indicated by the clinicaltrials.gov listing which was last updated on January 26th 2023. However, there are 163 active studies that people can join at this time." - Anonymous Online Contributor
Could you discuss the degree of safety associated with Deucravacitinib?
"There is an abundance of evidence suggesting Deucravacitinib's safety, which earns it a 3 rating on our scale. This drug has reached approval status in the Phase 4 trial process." - Anonymous Online Contributor